文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

儿童及青少年Diamond-Blackfan贫血造血干细胞移植结局良好

Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia.
PubMed 文献 · Blood Adv · 2020-01-01

该研究基于德国DBA注册库和法国HSCT注册库1985-2017年70例儿童DBA患者,评估异基因HSCT疗效。中位移植年龄5.5岁,64%为MSD,73%于1999年后移植。全部患者实现原发植入,无慢性GVHD生存率87%,且随时间显著改善(<2000年68% vs ≥2000年94%,P<.01)。

要点

  • HSCT可有效纠正DBA血液学表型,原发植入率100%。
  • 无慢性GVHD生存率87%,1999年后MSD移植无严重慢性GVHD或死亡。
  • 年轻DBA患者若有MSD或匹配UD,HSCT安全有效。

核心结论

  • HSCT对年轻DBA患者高效安全,有MSD或匹配UD时应考虑。
  • 仅因输血依赖对年龄较大患者行HSCT需谨慎讨论。

研究设计与样本

  • 回顾性注册研究,纳入德国DBA和法国HSCT注册库1985-2017年70例儿童DBA患者。
  • 中位移植年龄5.5岁(范围0.9-17.3岁),64%接受MSD移植,73%于1999年后移植。

主要发现

  • 全部患者实现原发植入,1例发生继发植入失败。
  • 急性GVHD °II-IV累积发生率24%(95%CI 16%-37%),°III-IV为7%(95%CI 3%-17%)。
  • 慢性GVHD累积发生率11%(95%CI 5%-22%)。
  • 无慢性GVHD生存率87%(95%CI 79%-95%),随时间显著改善(<2000年68%[95%CI 47%-89%] vs ≥2000年94%[95%CI 87%-100%],P<.01)。
  • MSD与UD移植后无慢性GVHD生存率相当;1999年后MSD移植无严重慢性GVHD或死亡。

关键数值与推荐

  • 急性GVHD °II-IV累积发生率24%(95%CI 16%-37%),°III-IV为7%(95%CI 3%-17%)。
  • 慢性GVHD累积发生率11%(95%CI 5%-22%)。
  • 无慢性GVHD生存率87%(95%CI 79%-95%)。
  • <10岁与10-18岁患者无慢性GVHD生存率差异无统计学意义(90%[95%CI 81%-99%] vs 78%[95%CI 58%-98%])。

临床怎么用

  • 年轻DBA患者若有MSD或匹配UD,HSCT可作为纠正血液学表型的治疗选择。
  • 对年龄较大、仅因输血依赖考虑HSCT者需审慎评估风险获益。

局限性

  • 回顾性注册研究,样本量70例,可能存在选择偏倚。
  • 移植时间跨度大(1985-2017),支持治疗和移植技术随时间变化可能影响结果。
  • 年龄<10岁与10-18岁无慢性GVHD生存率差异未达统计学显著性,可能受样本量限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diamond-Blackfan anemia (DBA) is a congenital pure red cell aplasia associated with congenital abnormalities and cancer predisposition. Allogeneic hematopoietic stem cell transplantation (HSCT) can correct the hematological phenotype and is indicated in transfusion-dependent patients. In 70 children reported to the German DBA and French HSCT registries, HSCT was performed from 1985 to 2017. Median age at HSCT was 5.5 years (range, 0.9-17.3 years). Two-thirds of patients (64%) were transplanted from a matched sibling donor (MSD), and most procedures were performed after the year 1999 (73%). Primary engraftment was achieved in all patients. One patient developed secondary graft failure. Cumulative incidence of acute graft-versus-host disease (GVHD) was 24% for °II-IV (95% confidence interval [CI], 16% to 37%) and 7% for °III-IV (95% CI, 3% to 17%); cumulative incidence of chronic GVHD was 11% (95% CI, 5% to 22%). The probability of chronic GVHD-free survival (cGFS) was 87% (95% CI, 79% to 95%) and significantly improved over time (<2000: 68% [95% CI, 47% to 89%] vs ≥2000: 94% [95% CI, 87% to 100%], P < .01). cGFS was comparable following HSCT from a MSD and an unrelated donor (UD). Of note, no severe chronic GVHD or deaths were reported following MSD-HSCT after 1999. The difference of cGFS in children transplanted <10 years of age compared with older patients did not reach statistical significance (<10 years: 90% [95% CI, 81% to 99%] vs 10-18 years 78% [95% CI, 58% to 98%]). In summary, these data indicate that HSCT is efficient and safe in young DBA patients and should be considered if a MSD or matched UD is available. HSCT for transfusion dependency only must be critically discussed in older patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Strahm B, Loewecke F, Niemeyer CM, et al. Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia. Blood Adv. 2020. PMID: 32343795. doi:10.1182/bloodadvances.2019001210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。